Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VRTX

Vertex Pharmaceuticals, Inc

Mar 12 • 04:00PM ET

495.42

Dollar change +7.08
Percentage change 1.45	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ SPY IVV VUG XLV IBB VHT QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-2.20	Insider Own	0.30%	Shs Outstand	256.94M	Perf Week	0.77%
Market Cap	127.22B	Forward P/E	24.09	EPS next Y	20.57	Insider Trans	-6.68%	Shs Float	256.01M	Perf Month	5.42%
Income	-535.60M	PEG	-	EPS next Q	4.27	Inst Own	93.25%	Short Float	2.14%	Perf Quarter	7.21%
Sales	10.98B	P/S	11.58	EPS this Y	4170.88%	Inst Trans	-4.01%	Short Ratio	3.29	Perf Half Y	5.16%
Book/sh	63.87	P/B	7.76	EPS next Y	14.67%	ROA	-2.32%	Short Interest	5.48M	Perf Year	19.79%
Cash/sh	23.83	P/C	20.79	EPS next 5Y	-	ROE	-3.15%	52W Range	377.85 - 519.88	Perf YTD	23.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-2.96%	52W High	-4.70%	Beta	0.50
Dividend TTM	-	Quick Ratio	2.35	Sales past 5Y	28.35%	Gross Margin	86.07%	52W Low	31.12%	ATR (14)	12.92
Dividend Ex-Date	-	Current Ratio	2.69	EPS Y/Y TTM	-114.72%	Oper. Margin	-1.65%	RSI (14)	62.39	Volatility	3.08% 2.56%
Employees	6100	Debt/Eq	0.11	Sales Y/Y TTM	11.64%	Profit Margin	-4.88%	Recom	1.94	Target Price	505.73
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-5.61%	Payout	0.00%	Rel Volume	0.82	Prev Close	488.34
Sales Surprise	4.59%	EPS Surprise	-0.90%	Sales Q/Q	14.56%	Earnings	Feb 10 AMC	Avg Volume	1.67M	Price	495.42
SMA20	3.35%	SMA50	9.56%	SMA200	5.92%	Trades		Volume	1,368,567	Change	1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold	$408 → $424
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell	$332 → $379
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform	$347 → $379
May-30-23	Initiated	William Blair	Outperform	$382

Show Previous Ratings

Today 02:29PM	Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds (Insider Monkey)
11:30AM	Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? (Zacks)
08:57AM	Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? (Insider Monkey)
Mar-11-25 05:31AM	Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever (Motley Fool)
05:05AM	3 Reasons to Avoid VRTX and 1 Stock to Buy Instead (StockStory)
04:25AM	Loading…
04:25AM	Where Will Vertex Pharmaceuticals Be in 10 Years? (Motley Fool)
Mar-10-25 08:30AM	If I Could Buy Only 1 Growth Stock, This Would Be It (Motley Fool)
Mar-08-25 10:41AM	3 Magnificent Growth Stocks to Buy in March (Motley Fool)
Mar-07-25 10:02AM	Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis (Business Wire)
Mar-04-25 06:15AM	5 Top Stocks to Buy in March (Motley Fool)
Feb-28-25 07:22AM	Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations (Business Wire)
Feb-25-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology)
Feb-24-25 04:50PM	Vertex's FDA Win: A Billion-Dollar Bet on Safer Pain Treatment (GuruFocus.com)
Feb-23-25 01:17PM	Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolios Top Stock Picks (Insider Monkey)
05:47AM	Loading…
Feb-22-25 05:47AM	3 Magnificent Growth Stocks to Buy Right Now (Motley Fool)
Feb-21-25 05:50AM	2 No-Brainer Healthcare Stocks to Buy With $500 Right Now (Motley Fool)
Feb-18-25 04:05PM	Vertex to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-17-25 04:32AM	3 Stocks That Could Trounce the Market in 2025 (Motley Fool)
Feb-15-25 08:45AM	2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 (Motley Fool)
Feb-14-25 12:20PM	CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99 (GuruFocus.com)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
05:47AM	The Ultimate Healthcare Stock to Buy With $500 Right Now (Motley Fool)
04:35AM	Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing (Motley Fool)
Feb-12-25 09:41AM	Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank (TipRanks)
09:41AM	Vertex Pharmaceuticals price target raised to $520 from $460 at Truist (TipRanks)
Feb-11-25 10:01PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
04:12PM	Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. (Investor's Business Daily)
09:15AM	Vertex: Strong Sales, Stronger Pipeline (Motley Fool)
09:10AM	Q4 2024 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Loading…
02:06AM	Vertex Pharmaceuticals Inc (VRTX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-10-25 08:45PM	Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript (Motley Fool)
05:10PM	Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates (Zacks)
04:30PM	Vertex Pharmaceuticals' Revenue Forecast Tops Expectations (Investopedia)
04:17PM	Vertex Pharmaceuticalss (NASDAQ:VRTX) Q4 Sales Top Estimates (StockStory)
04:13PM	Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand (Reuters)
04:11PM	Vertex: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Vertex Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-09-25 11:15AM	2 Biotech Stocks to Buy Hand Over Fist in February (Motley Fool)
08:04AM	Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For (StockStory)
05:00AM	What To Expect in the Markets This Week (Investopedia)
Feb-05-25 09:15AM	Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics (Zacks)
Feb-04-25 07:10AM	Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? (Motley Fool)
Feb-03-25 05:50PM	Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note (Zacks)
09:30AM	3 Magnificent Stocks to Buy and Hold Forever (Motley Fool)
09:03AM	Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? (Zacks)
Feb-02-25 08:06AM	Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? (Motley Fool)
05:35AM	Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? (Motley Fool)
Feb-01-25 09:05AM	Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank (TipRanks)
Jan-31-25 04:17PM	These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More (Barrons.com) +5.31%
04:11PM	How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter (Investor's Business Daily)
12:38PM	These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More (Barrons.com)
12:16PM	AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute (Yahoo Finance Video)
12:08PM	Vertex stock jumps on FDA approval of new non-opioid painkiller (Yahoo Finance Video)
11:09AM	Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive (CNBC TV)
10:59AM	No Major Catalyst, Wells Fargo Downgraded Vertex (GuruFocus.com)
10:57AM	Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller (Barrons.com)
10:34AM	The FDA approved a new non-opioid painkiller. Its maker's stock is rising (Quartz)
09:56AM	Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval (Investopedia)
09:47AM	Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller (Investor's Business Daily)
07:47AM	NHS England to offer Casgevy for sickle cell disease patients (Pharmaceutical Technology)
04:36AM	FDA approves Vertexs acute pain treatment Journavx (Pharmaceutical Technology)
02:00AM	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease in England (Business Wire)
Jan-30-25 07:13PM	Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug (The Wall Street Journal)
06:25PM	Vertex Announces FDA Approval of JOURNAVX (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain (Business Wire)
02:50PM	Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)'s Suzetrigine: 'I Don't See A Lot Of Upside Because That Was The Drug Of The Future For Vertex' (Insider Monkey)
Jan-28-25 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Jan-27-25 10:00AM	Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline (Zacks)
07:30AM	Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 (Business Wire)
Jan-26-25 06:30AM	Is Vertex Pharmaceuticals Stock a Buy in 2025? (Motley Fool)
Jan-25-25 11:15AM	Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. (Motley Fool)
Jan-24-25 04:15AM	2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher (Motley Fool)
Jan-22-25 06:00PM	Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts (Zacks)
Jan-21-25 06:22PM	Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
Jan-18-25 06:40AM	3 Unstoppable Stocks to Buy in 2025 (Motley Fool)
Jan-16-25 06:00PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know (Zacks)
05:49AM	Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? (Motley Fool)
Jan-15-25 07:31PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
09:00AM	Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock (Zacks)
Jan-14-25 02:47PM	Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials (Benzinga)
Jan-13-25 04:48AM	My 3 Highest-Conviction Growth Stocks to Buy in 2025 (Motley Fool)
Jan-12-25 05:01PM	Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings (Business Wire)
Jan-11-25 07:41AM	Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement (TipRanks)
Jan-10-25 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know (Zacks)
08:42AM	Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials (Insider Monkey)
07:30AM	Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (Business Wire)
07:30AM	Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore (Business Wire)
Jan-08-25 07:21AM	Vertex and Orna sign partnership to improve efficiencies of gene therapies (Pharmaceutical Technology)
Jan-07-25 07:19AM	Vertex, startup Orna to partner on gene editing research (BioPharma Dive)
07:00AM	Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) (PR Newswire)
Jan-06-25 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-01-25 12:43PM	Jim Cramer's Take on Vertex Pharmaceuticals (VRTX): Bold Predictions for the Future (Insider Monkey)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-31-24 06:00PM	Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors (Zacks)
Dec-30-24 08:30AM	Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock? (Zacks)
Dec-28-24 08:00AM	Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip (Motley Fool)
Dec-26-24 08:30AM	Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip (Motley Fool)
Dec-25-24 07:51AM	Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): This Is Hardly Down For The Year. I Think It Can Still Go Lower (Insider Monkey)
07:51AM	Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): and#8216;This Is Hardly Down For The Year. I Think It Can Still Go Lower' (Insider Monkey)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10 '25	Sale	500.00	3,298	1,649,000	51,671	Mar 12 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 10 '25	Sale	499.99	3,242	1,620,968	51,239	Mar 12 04:10 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 10 '25	Sale	500.00	3,231	1,615,500	26,512	Mar 12 04:08 PM
Tatsis Ourania	Officer	Mar 10 '25	Proposed Sale	499.99	3,242	1,620,968		Mar 10 01:58 PM
WAGNER CHARLES F JR	Officer	Mar 10 '25	Proposed Sale	500.00	3,298	1,649,000		Mar 10 01:02 PM
ALTSHULER DAVID	Officer	Mar 10 '25	Proposed Sale	500.00	3,231	1,615,500		Mar 10 12:42 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 04 '25	Sale	485.49	4,058	1,970,118	54,481	Mar 06 04:08 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 03 '25	Sale	490.00	3,231	1,583,190	29,743	Mar 05 04:08 PM
Tatsis Ourania	Officer	Mar 04 '25	Proposed Sale	485.49	4,058	1,970,118		Mar 04 01:39 PM
ALTSHULER DAVID	Officer	Mar 03 '25	Proposed Sale	490.00	3,231	1,583,190		Mar 03 04:17 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27 '25	Sale	475.34	530	251,930	58,539	Feb 28 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 27 '25	Sale	475.34	2,650	1,259,651	19,352	Feb 28 04:36 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 27 '25	Sale	480.00	1,272	610,560	32,974	Feb 28 04:23 PM
ALTSHULER DAVID	Officer	Feb 27 '25	Proposed Sale	480.00	1,272	610,560		Feb 27 11:20 AM
Atkinson Edward Morrow III	Officer	Feb 27 '25	Proposed Sale	475.34	2,650	1,259,651		Feb 27 10:18 AM
Tatsis Ourania	Officer	Feb 27 '25	Proposed Sale	475.34	530	251,930		Feb 27 10:14 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25 '25	Sale	480.95	354	170,256	64,031	Feb 26 04:15 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 25 '25	Sale	480.95	1,767	849,839	24,484	Feb 26 04:09 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 25 '25	Sale	480.95	884	425,160	9,086	Feb 26 04:06 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 25 '25	Sale	480.95	848	407,846	40,200	Feb 26 04:04 PM
Tatsis Ourania	Officer	Feb 25 '25	Proposed Sale	480.95	354	170,256		Feb 25 11:38 AM
ALTSHULER DAVID	Officer	Feb 25 '25	Proposed Sale	480.95	848	407,846		Feb 25 11:13 AM
Atkinson Edward Morrow III	Officer	Feb 25 '25	Proposed Sale	480.95	1,767	849,839		Feb 25 10:59 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 20 '25	Sale	480.00	1,111	533,280	45,019	Feb 24 04:07 PM
ALTSHULER DAVID	Officer	Feb 20 '25	Proposed Sale	480.00	1,111	533,280		Feb 20 03:45 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18 '25	Sale	455.06	244	111,035	67,695	Feb 19 04:36 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 18 '25	Sale	455.06	1,657	754,034	17,606	Feb 19 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 18 '25	Sale	455.06	671	305,345	10,798	Feb 19 04:21 PM
Tatsis Ourania	Officer	Feb 18 '25	Proposed Sale	455.06	244	111,035		Feb 18 11:34 AM
Biller Jonathan	Officer	Feb 18 '25	Proposed Sale	455.06	1,657	754,034		Feb 18 11:29 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 11 '25	Sale	459.83	310	142,547	64,021	Feb 12 04:50 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 11 '25	Sale	459.87	3,433	1,578,734	16,330	Feb 12 04:36 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 11 '25	Sale	459.83	1,747	803,323	23,225	Feb 12 04:29 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 11 '25	Sale	459.83	1,376	632,726	9,953	Feb 12 04:24 PM
Biller Jonathan	Officer	Feb 11 '25	Proposed Sale	459.87	3,433	1,578,744		Feb 11 11:57 AM
Tatsis Ourania	Officer	Feb 11 '25	Proposed Sale	459.83	310	142,547		Feb 11 11:05 AM
Atkinson Edward Morrow III	Officer	Feb 11 '25	Proposed Sale	459.83	1,747	803,323		Feb 11 09:49 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM
LEIDEN JEFFREY M	Executive Chairman	Aug 30 '24	Sale	499.00	3,784	1,888,216	9,994	Sep 04 04:13 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Option Exercise	152.74	646	98,670	5,081	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Sale	500.00	646	323,000	4,435	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Proposed Sale	500.00	646	323,000		Aug 30 04:47 PM
JEFFREY LEIDEN	Director	Aug 30 '24	Proposed Sale	493.35	3,784	1,866,836		Aug 30 04:23 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Option Exercise	152.74	1,292	197,340	5,727	Aug 12 04:08 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Sale	466.29	1,292	602,447	4,435	Aug 12 04:08 PM
Bozic Carmen	EVP and CMO	Aug 07 '24	Sale	476.75	2,280	1,086,990	23,259	Aug 08 04:06 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Proposed Sale	466.29	1,292	602,447		Aug 08 11:47 AM
Bozic Carmen	Officer	Aug 07 '24	Proposed Sale	476.75	2,280	1,086,990		Aug 07 09:52 AM
SACHS BRUCE I	Director	Aug 01 '24	Option Exercise	125.71	5,295	665,634	45,295	Aug 02 04:10 PM
SACHS BRUCE I	Director	Aug 01 '24	Sale	508.00	5,295	2,689,860	40,000	Aug 02 04:10 PM
Kewalramani Reshma	CEO & President	Jul 30 '24	Sale	505.00	15,202	7,677,010	90,970	Aug 01 04:17 PM
SACHS BRUCE I	Director	Aug 01 '24	Proposed Sale	508.00	5,295	2,689,860		Aug 01 03:34 PM
Kewalramani Reshma	Officer	Jul 30 '24	Proposed Sale	505.00	15,202	7,677,010		Jul 30 03:25 PM
Bozic Carmen	EVP and CMO	Jul 24 '24	Sale	488.46	2,280	1,113,689	25,539	Jul 25 04:06 PM
Kewalramani Reshma	CEO & President	Jul 22 '24	Sale	497.00	15,202	7,555,394	106,172	Jul 24 04:05 PM
Bozic Carmen	EVP and CMO	Jul 10 '24	Sale	487.34	2,280	1,111,135	27,819	Jul 12 04:07 PM
Bozic Carmen	EVP and CMO	Jun 26 '24	Sale	471.72	2,280	1,075,522	30,099	Jun 28 04:04 PM
Bozic Carmen	EVP and CMO	Jun 12 '24	Sale	478.00	2,280	1,089,840	32,379	Jun 13 04:11 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Jun 12 '24	Sale	478.00	7,288	3,483,664	15,972	Jun 13 04:09 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jun 03 '24	Sale	460.00	3,250	1,495,000	47,137	Jun 05 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jun 03 '24	Sale	460.00	2,175	1,000,500	49,098	Jun 05 04:08 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 30 '24	Sale	439.11	2,350	1,031,908	53,523	Jun 03 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 31 '24	Sale	445.00	2,250	1,001,250	51,273	Jun 03 04:09 PM
Bozic Carmen	EVP and CMO	May 29 '24	Sale	445.56	2,280	1,015,877	34,659	May 31 04:19 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 28 '24	Sale	454.79	3,250	1,478,068	50,387	May 30 04:07 PM
Kewalramani Reshma	CEO & President	May 24 '24	Option Exercise	187.53	1,565	293,484	122,939	May 29 04:08 PM
Kewalramani Reshma	CEO & President	May 24 '24	Sale	457.00	1,565	715,205	121,374	May 29 04:08 PM
SACHS BRUCE I	Director	May 22 '24	Option Exercise	93.51	7,073	661,396	47,073	May 24 04:13 PM
SACHS BRUCE I	Director	May 22 '24	Sale	448.00	7,073	3,168,704	40,000	May 24 04:13 PM
Kewalramani Reshma	CEO & President	May 20 '24	Sale	447.00	15,202	6,795,294	121,374	May 22 04:21 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	May 15 '24	Sale	430.93	32	13,790	55,325	May 17 04:27 PM
Arbuckle Stuart A	EVP, COO	May 15 '24	Sale	430.93	69	29,734	49,691	May 17 04:24 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '24	Sale	430.93	54	23,270	25,813	May 17 04:22 PM
Bhatia Sangeeta N.	Director	May 02 '24	Sale	402.95	467	188,178	4,435	May 03 04:05 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 02 '24	Sale	419.00	240	100,560	7,500	Apr 03 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience